A

Albireo Pharma Inc
F:BDQM

Watchlist Manager
Albireo Pharma Inc
F:BDQM
Watchlist
Price: 41.41 EUR 0.46% Market Closed
Market Cap: €857.2m

Relative Value

There is not enough data to reliably calculate the relative value of BDQM.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BDQM Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

BDQM Competitors Multiples
Albireo Pharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Albireo Pharma Inc
F:BDQM
856.9m EUR 17.6 -7.7 -7.5 -7.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 746 422.5 -160 391.7 -165 649.1 -163 758.9
US
Abbvie Inc
NYSE:ABBV
398.8B USD 6.7 169.8 16.4 23.3
US
Amgen Inc
NASDAQ:AMGN
185.3B USD 5.2 26.5 18.9 18.9
US
Gilead Sciences Inc
NASDAQ:GILD
177.3B USD 6.1 21.9 14.8 14.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120B USD 10.2 32.6 24 25.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.6 -532.7 -682 -663.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD 5.6 17.4 16.6 18.8
AU
CSL Ltd
ASX:CSL
85.8B AUD 3.8 19.5 9 11.2
NL
argenx SE
XBRU:ARGX
43.5B EUR 14.4 33.9 68.7 70.6
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -78.2 -70.5
P/S Multiple
Revenue Growth P/S to Growth
US
A
Albireo Pharma Inc
F:BDQM
Average P/S: 3 068 054.5
17.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 746 422.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
6.1
4%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 087.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
A
Albireo Pharma Inc
F:BDQM
Average P/E: 45.9
Negative Multiple: -7.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 391.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
169.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.5
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
21.9
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
10%
1.7
AU
CSL Ltd
ASX:CSL
19.5
11%
1.8
NL
argenx SE
XBRU:ARGX
33.9
42%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Albireo Pharma Inc
F:BDQM
Average EV/EBITDA: 24.1
Negative Multiple: -7.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 649.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.9
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.8
7%
2.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -682 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
9
8%
1.1
NL
argenx SE
XBRU:ARGX
68.7
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -78.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Albireo Pharma Inc
F:BDQM
Average EV/EBIT: 26.1
Negative Multiple: -7.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 758.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.8
13%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.1
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -663.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
11.2
11%
1
NL
argenx SE
XBRU:ARGX
70.6
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -70.5 N/A N/A